Table 1.
Patient demographics and baseline characteristics.
| Characteristics | Corifollitropin alfa/PPOS protocol (n = 173) | Corifollitropin alfa/GnRHant protocol (n = 160) | P value |
|---|---|---|---|
| Total no. of cycles | 173 | 160 | |
| Age (y) | 34.2 ± 2.8 | 34.4 ± 2.6 | 0.549 |
| Body weight (kg) | 55.8 ± 3.8 | 55.7 ± 3.7 | 0.795 |
| Body mass index (kg/m2) | 22.4 ± 1.8 | 22.4 ± 1.7 | 0.950 |
| Duration of infertility (y) | 3.4 ± 1.5 | 3.5 ± 1.6 | 0.844 |
| Proportion of primary infertility (%) | 80.1 (140/173) | 85.0 (136/160) | 0.382 |
| AMH (ng/mL) | 9.7 ± 4.2 | 10.1 ± 5.3 | 0.401 |
| Baseline hormonal profiles | |||
| FSH (IU/L) | 5.7 ± 1.4 | 5.8 ± 1.5 | 0.286 |
| LH (IU/L) | 6.5 ± 2.3 | 6.1 ± 2.5 | 0.166 |
| E2 (pg/mL) | 40.2 ± 17.6 | 41.8 ± 16.8 | 0.392 |
| Progesterone (ng/mL) | 0.65 ± 0.25 | 0.69 ± 0.22 | 0.149 |
| Testosterone (ng/dL) | 34.5 ± 18.0 | 35.6 ± 17.4 | 0.553 |
Values are expressed as number, mean ± standard deviation or percentage.
PPOS progestin primed ovarian stimulation, GnRHant GnRH antagonist, AMH anti-Mullerian hormone, FSH follicle-stimulating hormone, LH luteinizing hormone, E2 Estradiol.